Given the modest results with IDH1mut inhibitors in chondrosarcoma [42], future efforts to improve the efficacy of these compounds might benefit from emphasis on biology-driven therapeutic strategies to improve response rates in IDH-mutated chondrosarcomas. The gene discussed is IDH1; the disease is chondrosarcoma.